The Last Section: Tissue Stewardship and the Hidden Cost of Block Exhaustion

Every histotech knows the moment. A block comes back for more unstained slides. The first cuts look fine. Then there's a little less tissue on the next pass, and less again, and you start facing deeper to chase it. Somewhere in that ribbon you feel the work shift from cutting tissue to spending it. Someone asks whether you can just cut more, but the block has already answered. The cassette is still there. The paraffin is still there. The thing that mattered, the tumor or lesion or interface or region of interest, is mostly behind you on slides that may or may not have been worth it.

We tend to file this under microtomy: a facing problem, a water-bath problem, a bad-block problem. It is almost never only that. Block exhaustion is where decisions made long before the microtome, and long after the first slide is read, finally come due. The histotech just happens to be standing at the blade when the bill arrives.

Stewardship preserves options, not just tissue

Tissue stewardship is the discipline of managing a specimen so that the most important questions can still be answered, including the ones nobody has asked yet. It runs the whole length of the workflow: acquisition, fixation, processing, embedding orientation, facing depth, section thickness, how many blanks, how we label and store, what the recut policy is, and who we talk to before we overcut.

Communication is the part that gets dropped. A single careful pass at the microtome is not the whole of it, and neither is a careful hand acting alone. What stewardship really protects is the block's future testability, against a stream of requests that don't realize they are competing for the same material. A patient's molecular send-out draws down the same block as the repeat IHC that failed for a fixation reason. A study's pharmacodynamic readout draws on the same tissue as the assay optimization someone ran on the rare block instead of on control material. Good stewardship keeps those claims from colliding for as long as possible.

Functionally exhausted, technically present

It helps to be precise about exhaustion, because the cassette can mislead you. A block is exhausted when the remaining tissue can no longer support what's still needed: deeper levels, a repeat stain, molecular extraction, an outside review, a future recurrence workup.

The distinction is one histology feels before anyone else does. A block can be technically present and functionally exhausted at the same time. The paraffin is full and the label is intact, yet the lesion lived at one depth and that depth is gone. From across the room it still reads as a block. On the slide, it reads as a record of something you cannot get back.

Two settings, one finite block

Clinical and pharma histology look like different worlds, and the pressures on the block really are different. The block itself does not change.

In clinical work, the squeeze comes from how much a single small biopsy now has to carry. One core may need an H&E diagnosis, initial IHC classification, predictive IHC, ISH or FISH, a tumor-percentage assessment, molecular curls, a clinical-trial screen, a repeat if something fails, and an outside consult, sometimes all of it. A thoracic pathology working group put it plainly: tissue from small biopsy and cytology specimens is a precious and finite resource, and the list of required biomarkers keeps growing. Their recommendation for suspected lung cancer is instructive, because it locates stewardship before the block ever reaches the microtome. Anticipate the downstream predictive testing, they say, and conserve tissue from the start.

In pharma and preclinical work, the block is more often exhausted by development than by diagnosis. A xenograft or tox block may be asked to support target screening, assay optimization, positive and negative controls, a pharmacodynamic marker, species discrimination, multiplex IHC or IF, digital image analysis, GLP archival, and repeat work after a sponsor or pathologist review. The stakes hide in what the sample represents: a unique animal, a single dose group, a rare time point, an expensive model, the one responder or non-responder in the cohort. Burn that block on preventable troubleshooting and you have not lost a slide. You have weakened an endpoint.

The consequences differ, but the ethic is the same. Clinical labs protect patient care; pharma labs protect scientific validity. Underneath both runs one quiet agreement, that the block is finite from the first cut rather than a realization saved for the last.

How blocks actually get exhausted

The causes fall into three stages, and only one of them is at the blade.

Before the block arrives, exhaustion is set in motion by poor or delayed fixation, oversized pieces, weak orientation, and a grossing strategy blind to the testing still to come. Toxicologic pathology guidance keeps returning to this point: sampling, fixation, trimming, orientation, and artifact awareness are central to reliable histology, and a pathologist who doesn't understand them makes the histotech's job harder and the data softer. Upstream drift becomes downstream interpretation failure, and the slide is where it finally shows.

At the microtome, the familiar culprits take over: over-facing, excessive trim between levels, a few extra blanks cut "just in case" with no plan attached to them, repeated failed sections, water-bath trouble, chatter and compression forcing recuts. Beneath all of it sits the deeper problem of cutting without knowing which request actually has priority.

In the workflow around the block, the damage is quieter. Unclear stain requests, duplicate orders, optimization run on rare study tissue rather than controls, whole blocks sent out when curls or scrolls or digital images would have done, and no one tracking how much tissue is left. The worst offender is the request that arrives with no reason attached. Cut twenty unstained, with no assay plan. Run the whole panel, when a narrower decision tree would answer the question. Repeat it, without anyone checking whether the failure was antibody, detection, fixation, tissue type, or interpretation. Each of those costs material, and the cost stays invisible to whoever placed the order.

The judgment we don't get credit for

This is the part worth sitting with. The histotech is usually the first person to physically see that a block is running out. Not the pathologist reading the finished slide, not the molecular lab waiting on curls, not the study director three steps removed. The person at the microtome watches the tissue disappear in real time, sees that the lesion is present at only one level, recognizes that the next deep cut may destroy the region of interest, and notices when the request simply doesn't match what's left in the block.

We get described as slide producers. The stewardship lens reveals something closer to a gatekeeper. Should I face deeper or stop? Is this enough tissue on the slide to be diagnostic, or to satisfy the assay? Do I cut blanks now or wait? Is this block thin enough that I should pause and escalate before the last usable section is gone? None of that is robotic. These are judgment calls made under time pressure, often with no clear sense of why the slide was ordered, and they decide whether tomorrow's question can still be answered.

What stewardship looks like on the bench

When it works, a handful of habits are usually doing the quiet work.

1. Purpose ranks the cut. Diagnosis, predictive testing, molecular extraction, a study endpoint, and assay optimization aren't equal claims on the same block, and the work goes better when they're ranked rather than queued. The same logic decides whether extra blanks are an asset or just spent tissue in a drawer: it depends on whether a plan is attached to them.
2. Controls absorb the troubleshooting. When optimization can run on control material, the rare clinical or study block stays intact for the question it was actually saved for.
3. The cut protects the region of interest, not just "tissue." Having tissue on the slide isn't the win. Having the tumor, the invasive front, the necrotic edge, the graft, the implant site, or the target-bearing area is, and that's what a careful pass keeps in reach.
4. A thin block starts a conversation early. The escalation that matters happens before the last good section, not as a post-mortem after it.
5. Documentation and SOPs carry it past any one person. Recording depths, levels, failures, and remaining-tissue concerns turns individual judgment into lab memory. CAP's specimen-handling guidance already supports defining the variables underneath all of this, from section thickness and slides per tissue type to trim between ribbons and labeling. Habit alone doesn't survive staff turnover.

It was never only the person at the blade

The honest conclusion is that block exhaustion rarely traces to one person, which is exactly why it keeps happening. The block passes through surgeons and interventional radiologists, grossing staff, pathologists, histotechs, the molecular lab, oncologists, study directors, biomarker leads, CROs, sponsors, and QA. Any of them can spend tissue by how they acquire it, orient it, order against it, or send it out. The consequence lands in one place. Histology is where the shortage becomes visible and where there is nothing left to do about it. Multidisciplinary planning, the kind clinical guidelines recommend for procurement and prioritization, exists precisely so the block is not rationed one uncoordinated request at a time. Stewardship should be shared. For now, histology absorbs it.

The block is a finite archive

A paraffin block is not yesterday's specimen filed away. It is a remaining chance to answer tomorrow's question: the recurrence workup, the new biomarker, the repeat endpoint, the consult no one has requested yet. Tissue does not regenerate inside paraffin. Every section that comes off a block should be able to say what it was for.

The best histotechs do not simply cut tissue. They protect what the tissue may still need to say.